David Woessner: What will be the next #immunooncology drug to gain approval by the #FDA? Will it be $BMY's Nivolumab in the PD-1 relm or a PD-L1 inhibitor?
13 hours and 14 minutes ago
Ambrot Capital: This week's earnings report focus: $AMZN $MSFT $P $UA $CAT $WYNN $GM (Thur) $F $PG $BMY $CL (Fri) #watchlist
16 hours and 44 minutes ago